Celldex Therapeutics, Inc (NASDAQ:CLDX) Advances Toward Near-Term Catalysts With Positive Trial Updates
![]() |
Clinical-stage momentum and a heavy cash position place the company under the spotlight as multiple trial readouts and corporate updates approach. Recent Phase 2 data and corporate filings compress the information set ahead of forthcoming Phase 3 topline milestones. |









